Atezolizumab, avelumab, and durvalumab are FDA-approved monoclonal antibodies that target PD-L1 for various cancers, including melanoma, non-small cell lung cancer, urothelial carcinoma, and metastatic triple-negative breast cancer [81,82,83]. This evidence concerns the gene CD274 and melanoma.